New drug combo shows promise in controlling Early-Stage leukemia
NCT ID NCT02689440
First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 28 times
Summary
This study tests whether combining two drugs, dasatinib and venetoclax, can better control early chronic phase chronic myeloid leukemia (CML). About 155 adults with newly diagnosed CML (within 12 months) who have had little or no prior treatment are participating. The goal is to reduce cancer cells to very low levels and monitor side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.